Abstract
In March 2010, the U.S. Food and Drug Administration approved the SynCardia Freedom Driver (SynCardia Systems Inc, Tucson, AZ) for an investigational device exemption study. We report the first use in our institution of the SynCardia temporary total artificial heart (TAH-t) Freedom Driver in a 41-year-old African American man (body surface area, 2.1 m2) 12 years after he underwent orthotopic heart transplant for anti-cardiolipin antibody-related thrombotic infarction.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
